TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to MICU with respiratory failure and intubated~* ARDS criteria per Berlin definition~* PaO2:FiO2 ratio ≤ 200 mmHg for \> 6 hours with FiO2 ≥0.5~* Expected to require mechanical ventilation for \>48 hours~* Reversible disease~Exclusion Criteria:~* Anticoagulation contraindicated~* Proven HIT~* Unable to obtain central venous access~* Refractory hypoxia (PaO2:FiO2 ≤80 after recruitment and proning) or other indication for ECMO~* Home oxygen use~* Severe COPD~* Interstitial lung disease~* \> 7 days of mechanical ventilation~* Immunocompromised patient (bone marrow, untreated HIV, PJP)~* Advanced malignancy with life expectancy ≤ 6months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Conventional lung protective ventilation (Type: ACTIVE_COMPARATOR): Lung protective ventilation (6ml/kg predicted body weight). All other interventions per intensive care unit standardised ARDS management protocol
- Ultra-protective ventilation (Type: EXPERIMENTAL): Ultra-protective ventilation (\</= 3ml/kg predicted body weight) targeting plateau pressure of \</= 25 cmH2O, supported by Prismalung. All other intervention per intensive care unit standardised ARDS management protocol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with traumatic or medical spinal cord injury~* Age of 18 years or above~* Patients who need an indwelling urinary catheter as a method of bladder drainage for at least 7 days.~* Patients who are willing to participate in the study and give their written informed consent (If a patient is unable to give written consent because of physical or mental disability, an affirmation of consent will be taken in his presence from his relative or legal guardian).~Exclusion Criteria:~* Patients who can benefit from other method of bladder drainage such as intermittent catheterization, suprapubic drainage, reflex voiding or use of an external collector.~* Patients with urinary tract infection at the moment of inclusion~* Current antibiotic use or use within 7 days prior to inclusion~* Outpatients with sporadic medical examinations (less than one per month)~* Known allergy to latex, silver salts or hydrogels.~* Patients with surgical interventions in the urinary tract that may interfere, at the investigator criteria, with the study results.~* Pregnant or breastfeeding woman.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Silver Alloy-Coated Urinary Catheters (Type: EXPERIMENTAL): Bactiguard® Infection Protection coating consists of noble metals such as gold, palladium and silver. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.
- Conventional Urinary Catheter (Type: OTHER): Conventional or standard urinary catheters are those commonly used in each study center, most of them made of silicone or silicone-latex. Trained health staff performs urethral catheterization and select the most adequate catheter size. To ensure aseptic conditions they are asked to strictly follow the current protocol in their respective centers. Indwelling urethral catheters are periodically replaced about 30 days of use; to not interfere with current clinical practice, the policy of each center (or the investigator criteria) for catheter replacement and removal is considered valid for this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Detection of Cardiac Toxicity in Childhood Cancer Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects that have received anthracycline based chemotherapy~* Age: 8 years old - 25 years old~* Subjects that do not require sedation for cardiac MRI.~* Subjects must have completed treatment in the last 10 years~Exclusion Criteria:~* Patients with significant congenital heart defects~* Patients with renal injury or renal failure, defined as an estimated glomerular filtration rate \[eGFR\] \<30 ml/min/1.73 m2 body surface area), as previously calculated)~* Patients that require sedation for a cardiac MRI~* Subjects that are pregnant or lactating~* Patients with contraindications to a cardiac MRI:~* Cardiac pacemaker or implantable defibrillator~* Cerebral aneurysm clip~* Neural stimulator~* Metallic ocular foreign body~* Any implanted device (i.e. insulin pump, drug infusion device)~* Claustrophobia~* Metal shrapnel or bullet~* Investigator assessment of inability to comply with protocol~* Unable/unwilling to lie still throughout the research procedure~* Persons with cognitive impairment

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient or family able and willing to give informed consent.~2. Subjects with metastatic cancer to the brain who have failed at least one conventional therapy (surgery, stereotactic radiosurgery, and/or whole brain radiotherapy). Failure is defined as local recurrence or failure of the previously treated lesion and will be determined by the treating surgeon based on a review of patient history and imaging.~3. Tumor size \</= 3.0 cm in largest diameter.~4. MR imaging is not contraindicated for the patient~5. Lesion(s) are clearly defined on pre-therapy contrast enhanced MRI scans as determined by the treating surgeon.~6. Able and willing to attend all study visits.~7. Karnofsky Performance Scale score \>/=70 for patients over the age of 15.~8. Lansky Play Scale\>/=70 for patients 15 years of age or younger.~Exclusion Criteria:~1. Patients or family unwilling or unable to give written consent.~2. Patients who cannot physically fit in, or are too heavy for, the BrainSUITE® MRI scanner~3. Patients with contra-indications to MRI imaging, such as, but not limited to, pacemakers or defibrillators, non-compatible aneurysm clips, shrapnel, or other internal ferromagnetic objects~4. Known sensitivity to gadolinium-DTPA~5. Based on Treatment Planning Imaging (MR and/or CT) done on the day of treatment: -Brain edema and/or mass effect that causes midline shift or shift in wall of ventricle of more than 5 mm. -Lesions localized in the brain stem or the posterior fossa. -Lesions less than 5mm from primary branches of cerebral vessels, venous sinus, hypophysis or cranial nerves. -Evidence of recent (\<2 weeks) hemorrhage.~6. Symptoms and signs of increased intracranial pressure~7. Medical issues which prohibit the patient from undergoing surgery (as determined by the treating surgeon, anesthesiologist, IMPAC clinic, referring physician).~8. Patients who are unable to received corticosteroids.~9. Positive pregnancy test for women of child-bearing age.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laser Interstitial Thermal Therapy (Type: EXPERIMENTAL): Laser Interstitial Thermal Therapy (LITT) - An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing scoliosis repair~* ASA physical status classification system (ASA) I-III~Exclusion Criteria:~* Pre-existing chronic kidney disease~* Oropharyngeal disease, e.g. pharyngitis~* Esophageal disease, e.g. heartburn, esophageal varices or hiatus hernia.~* Coagulopathy~* Scheduled for two stage procedures

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Fluid management, boluses of 5ml/kg of plasmalyte, will follow a specific goal-directed fluid therapy (GDT) protocol guided by transesophageal doppler measurement
- Control group (Type: EXPERIMENTAL): Fluid management, using boluses of 5ml/kg of plasmalyte, will follow the current standard of care guided by clinical judgment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has undergone primary THA for any of the following:~* Non-inflammatory degenerative joint disease such as osteoarthritis, avascular necrosis, ankylosis, protrusio acetabuli, or painful hip dysplasia;~* Inflammatory degenerative joint disease such as rheumatoid arthritis; or~* Correction of functional deformity~* Subject is implanted with the specified combination of components~* Subject is willing and able to complete required study visits or assessments~Previously implanted bilateral subjects can have both THAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Investigator Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second THA. Prospective enrollment of a previously unimplanted hip is not permitted in this study.~Exclusion Criteria:~* Subjects skeletally immature (less than 21 years of age) at time of primary THA surgery~* Subjects currently enrolled in another clinical study which could affect the endpoints of this protocol~* Subjects unwilling to sign the Informed Consent document~* Subjects with substance abuse issues~* Subjects who are incarcerated

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PROFEMUR® Gladiator HA Coated Stem (Type: None): Single study group previously implanted with a primary PROFEMUR® Gladiator HA Coated Modular Femoral Stem (HA = Hydroxyapatite)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients older than 15 years and younger than 46 years.~2. Primary breast cancer (Stage I, II, or III).~3. Pathologically confirmed invasive breast carcinoma.~4. Negative hormone-receptor status. (Negative defined as ER- and PR- staining in less than 10% of tumor cells, or tumors with less than or equal to 3 fm/mg cytosol protein on ligand-binding or enzyme-linked immunoassay).~5. Premenopausal, verified before chemotherapy is begun as satisfying both:~   * Cyclic vaginal bleeding.~  * Follicle-stimulating hormone (FSH) is less than or equal to 15 IU/L. If patients are taking oral contraceptives, FSH must be measured 1-2 weeks after discontinuation. If FSH is greater than 15 and the patient has regular menses, gynecologic consultation will be required for a decision on premenopausal status.~6. Candidates for neoadjuvant and/or adjuvant chemotherapy for primary breast cancer.~7. Treatment with at least four (4) cycles of chemotherapy as planned.~8. Zubrod performance score of 0 or 1.~9. Must consent to preservation of their ovarian function and indicate their awareness of the investigational nature of this study, in keeping with institutional policy.~10. Willingness to use barrier contraception if sexually active.~Exclusion Criteria:~1. Pregnancy. Women must have a negative serum pregnancy test before initiation of injection.~2. Hypersensitivity to any GnRH analog.~3. Previous receipt of systemic chemotherapy.~4. To receive at least 4 cycles of neoadjuvant and/or adjuvant chemotherapy with CMF.~5. Stage IV breast cancer.~6. Prothrombin time (PT) and partial prothrombin time (PTT) with INR \> 1.5~7. Platelets \< 50,000/mm\^3

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: 46 Years
- Healthy Volunteers: f

Study Arms:
- Goserelin (Type: EXPERIMENTAL): 3.6 mg subcutaneously 1 week before chemotherapy, then once a month until 3 weeks after chemotherapy.
- No Goserelin (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Clinical and Biological Consequences of Levothyrox® Formula Modification

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Thyroid disorder treated by Levothyroxine~* Age over 18 year old~* TSH plasma level within the 12 months before formulation modification~* TSH plasma level within the 6 months after formulation modification~Exclusion Criteria:~- Thyroid dysfunction (hypo or hyperthyroidism) despite Levothyroxine treatment, ie TSH plasma level out of normal range within the 6 months before formula modification

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent/assent from the subject and/or a legal representative prior to initiation of any study-mandated procedures.~* Subjects who have completed Week 52 of the parent AC-055H301/RUBATO DB study (NCT03153137)~* Women of childbearing potential must:~  1. have a negative serum pregnancy test prior to first intake of OL study drug, and,~ 2. agree to perform monthly pregnancy tests up to the end of the safety follow up (S-FU) period, and,~ 3. use reliable methods of contraception from enrollment up to at least 30 days after study treatment discontinuation.~Exclusion Criteria:~* Clinical worsening leading to medical interventions including reoperation of Fontan circulation (Fontan take-down) during the enrollment period~* Systolic blood pressure \< 90 mmHg (\< 85 mmHg for subjects \< 18 years old and \< 150 cm of height) at rest~* Criteria related to macitentan use~* Any known factor or disease that may interfere with treatment compliance or full participation in the study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label treatment period (Type: EXPERIMENTAL): oral administration of 10 mg macitentan once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects aged 18-70 years~2. Patients with diagnosis of diffuse large B-cell lymphoma~3. Patients at high risk of CNS involvement (\>2 extranodal sites plus an elevated LDH or /and involvement of high-risk extranodal sites including testes, paranasal sinuses, breast, liver, adrenal and renal)~4. Patients who will receive HDMTX (three cycles) into R-CHOP regimen (6 cycles) prescribed according to normal clinical practice~5. Absence of focal neurological signs~6. Absence of CNS involvement determined by cerebrospinal fluid (CSF) cytometry flow test prior to start treatment~7. Eastern Cooperative Oncology Group (ECOG) performance status 0-2~8. Absolute neutrophil count 1800-7500/µL, platelet count 130.000- 450.000/ µL, hemoglobin 13,5-18 g/dL,~9. Serum creatinine ≤1.5 x the upper limit of normal (ULN) or glomerular filtration rate (GFR) ≥60ml/min/1.73m\^2~10. Total serum bilirubin ≤2 x ULN. Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5 x ULN~11. Ability to understand and the willingness to sign a written informed consent document~12. In women of childbearing potential (from menarche and until becoming post-menopausal \[i.e., no menses for 12 months with an alternative medical cause\], unless permanently sterile) and men, use of highly effective measure of contraception (abstinence, hormonal contraception, intra-uterine device \[IUD\], intrauterine hormone-releasing system, \[IUS\], or anatomical sterility in self or partner) committed during 3 months after the last IMP administration.~Exclusion Criteria:~1. Malignant disease, other than those being treated in this study. Exceptions to this exclusion include malignancies that were treated curatively and have not recurred within 2 years after completion of treatment.~2. Patients suffered from cardiovascular diseases (arrhythmias, previous heart failure, thromboembolic disease)~3. Previous treatment with Glucarpidase~4. Pregnant or breastfeeding women~5. Concomitant treatment with agents which interact with methotrexate metabolism or excretion~6. Known intolerance/hypersensitivity to Glucarpidase or any of its excipients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Glucarpidase, methotrexate, R-CHOP (Type: EXPERIMENTAL): Glucarpidase 2000Units per dose. IV. Bolus injection over 5 minutes. Administered 12 hours following after each HDMTX cycle, for a maximum of 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of the SurgiStim3 Electrical Stimulation Device in Persons Undergoing Anterior Cruciate Ligament Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Agree to provide informed consent to be included within this ACL study~* Demonstrate a continued willingness to be compliant with the parameters established under the study;~* Have no history of drug or alcohol abuse in the last 2 years;~* Be either a male or female adult between the ages of 18 and 64;~* Be undergoing a surgical repair of the anterior cruciate ligament (ACL) using either a hamstring, patella tendon, Achilles tendon, or allograft procedure; and~* Understand that there is no financial remuneration for participation in the study.~Exclusion Criteria:~* Pregnant women~* Insulin dependent diabetic patients~* Patients with a demand type pacemaker~* Patients who have a malignant tumor (other than basal cell epithelioma)~* Patients with a known history of alcohol or drug abuse in the last 2 years~* Patients who will not agree to provide informed consent to be included within this ACL study~* Patients who demonstrate a continued unwillingness to be compliant with the parameters established under this study.~* Poor healers as identified by the patient's medical history~* Patients who have a history of sensitivity to surgical tape, electrode adhesives, etc.~* Patients with a known history of RSD (reflex sympathetic dystrophy)~* Patients with a history of chronic pain (on opiates or high dosage of NSAIDS for 3 months or greater)~* Patients who have previously undergone an ACL reconstruction on the same knee~* Patients with clinically varicose veins (clinically significant or symptomatic)~* Patients whose history shows an abuse of diuretics or anti-inflammatory medications~* Patients who will undergo multiple ligament surgery (i.e., ACL plus PCL, MCL, and/or LCL)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues